These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 9576288

  • 1. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ, Dillman RO, Schulof R, Wiemann MC, Barth NM, Honeycutt PJ, Soori G.
    Cancer; 1998 May 01; 82(9):1677-81. PubMed ID: 9576288
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.
    Cancer Biother Radiopharm; 2000 Oct 01; 15(5):487-94. PubMed ID: 11155820
    [Abstract] [Full Text] [Related]

  • 3. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH, Atzpodien J, Poliwoda H.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():44-9. PubMed ID: 8692119
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
    Stein ME, Bernstein Z, Tsalic M, Drumea K, Steiner M, Sklar Z, Haim N.
    Am J Clin Oncol; 2002 Oct 12; 25(5):460-3. PubMed ID: 12393984
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N.
    Melanoma Res; 1999 Oct 12; 9(5):503-9. PubMed ID: 10596917
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun 12; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
    Schachter J, Rakowsky E, Sulkes A, Adler A.
    Cancer Biother Radiopharm; 1998 Jun 12; 13(3):155-64. PubMed ID: 10850351
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
    Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, Weiss GR, Sondak VK.
    J Cancer Res Clin Oncol; 1999 Jun 12; 125(5):292-6. PubMed ID: 10359134
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
    Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, Favaretto AG, Cetto GL, Monfardini S.
    Melanoma Res; 2001 Apr 12; 11(2):189-96. PubMed ID: 11333130
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P, Iannucci A, Becker M, Allen J, O'Driscoll M, McDowell K, Williams P, Rosse P, Murphy J, Gonzalez R.
    Melanoma Res; 2000 Apr 12; 10(2):171-9. PubMed ID: 10803718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.